Slingshot members are tracking this event:

Celgene Expected to Complete Four Phase 3 Trials of ABRAXANE in Different Indications in 2017

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks



Additional Information

Additional Relevant Details Celgene expects to complete four phase 3 studies of abraxane in four different indications.  Two studies are sponsored by Roche and study abraxane in combination with atezolizumab in squamous and non-squamous non-small cell lung cancer.  The other two study abraxane treatment on pancreatic cancer and squamous NSCLC maintenence.  Data for all studies expected to release 2017.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jan 19, 2018
Occurred Source:
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Abraxane, Phase 3 Clinical Trials, Pancreatic Cancer, Non-small Cell Lung Cancer